Log In
Print
BCIQ
Print
Print this Print this
 

BAN2401

  Manage Alerts
Collapse Summary General Information
Company BioArctic Neuroscience AB
DescriptionHumanized conformational specific IgG1 mAb targeting the toxic beta amyloid protofibrils
Molecular Target Beta amyloid
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation

Partner

Biogen Inc.; Eisai Co. Ltd.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$100.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today